ArticleThe neuroradiology journal2015
Vigabatrin-induced MRI changes associated with extrapyramidal symptoms in a child with infantile spasms.
Article in The neuroradiology journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Vigabatrin-Associated Brain Abnormalities on MRI in a Patient with PCDH19-Clustering Epilepsy.Journal of clinical medicine · 2026Article
- Vigabatrin-associated brain abnormalities on MRI (VABAM) in children with epileptic spasms.Pediatric research · 2026Observational
- Exploratory investigation of urinary alkanes and other volatile organic compounds in paediatric patients with tuberculous meningitis.Metabolomics : Official journal of the Metabolomic Society · 2025Article
- Brazilian experts' consensus on the treatment of infantile epileptic spasm syndrome in infants.Arquivos de neuro-psiquiatria · 2023Article
- Effectiveness of ACTH in Patients with Infantile Spasms.Brain sciences · 2022Article
- Periodic electroencephalographic discharges and epileptic spasms involve cortico-striatal-thalamic loops on Arterial Spin Labeling Magnetic Resonance Imaging.Brain communications · 2022Article
- Pharmacotherapy for Seizures in Tuberous Sclerosis Complex.CNS drugs · 2021Review
- Modulation of vigabatrin induced cerebellar injury: the role of caspase-3 and RIPK1/RIPK3-regulated cell death pathways.Journal of molecular histology · 2021Article
- Acute Movement Disorders in Childhood.Journal of clinical medicine · 2021Review
- Vigabatrin-associated Reversible MRI Abnormalities in an Infant with Tuberous Sclerosis.Journal of radiology case reports · 2021Article
- Preclinical tissue distribution and metabolic correlations of vigabatrin, an antiepileptic drug associated with potential use-limiting visual field defects.Pharmacology research & perspectives · 2019Article
- 2-Pyrrolidinone and Succinimide as Clinical Screening Biomarkers for GABA-Transaminase Deficiency: Anti-seizure Medications Impact Accurate Diagnosis.Frontiers in neuroscience · 2019Article
- The Pharmacology and Toxicology of Third-Generation Anticonvulsant Drugs.Journal of medical toxicology : official journal of the American College of Medical Toxicology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vigabatrin is an antiepileptic drug used for treatment of infantile spasms. We present a female patient with infantile spasms in treatment with vigabatrin who developed ataxic movements. MRI demonstrated a symmetrical pattern of thalamic and globi pallidi diffusion restriction. While these image features have been widely described to be related to the use of vigabatrin, this case highlights the development of movement disorders in association with MRI signal changes. Awareness of the reversible nature of this condition is reassuring for the treating team and avoids unjustified studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.